Page 2 - Brian Mckelligon News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Brian mckelligon. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Brian Mckelligon Today - Breaking & Trending Today

Akoya Biosciences (NASDAQ:AKYA) Price Target Cut to $6.00 by Analysts at Canaccord Genuity Group

Akoya Biosciences (NASDAQ:AKYA – Free Report) had its price objective cut by Canaccord Genuity Group from $10.00 to $6.00 in a report issued on Tuesday morning, Benzinga reports. They currently have a buy rating on the stock. A number of other brokerages have also recently weighed in on AKYA. BTIG Research dropped their price target […] ....

United States , Asia Pacific , Brian Mckelligon , Akoya Biosciences , Canaccord Genuity Group , Akoya Biosciences Inc , Schonfeld Strategic Advisors , Akoya Biosciences Company Profile , Asset Management Inc , Tower Research Capital , York Mellon Corp , Nisa Investment Advisors , Jpmorgan Chase Co , Free Report , Moderate Buy , Get Free Report , Investment Advisors , Research Capital , Management Inc , Strategic Advisors , New York Mellon Corp , North America , Middle East , Akoya Biosciences Daily ,

Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients

Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United States , New York , Neracare Gmb , Friedrich Ackermann , Neracare Immunoprint , Akoya Bioscience , Brian Mckelligon , Priyam Shah , Akoya Biosciences , Spatial Biology Company , Akoya Biosciences Inc , Exchange Commission , Neracare Enter , Exclusive Agreement , Enable Personalized Therapy Selection , Early Stage Melanoma , Financial Condition , Investor Contact , Media Contact , Care Contact ,